Clinical experience with drug delivery systems as tools to decrease the toxicity of anticancer chemotherapeutic...

Area of Science:

• Oncology
• Nanotechnology
• Pharmacology

Background:

• Chemotherapeutic agents possess a low pharmacological index, leading to significant toxicity and risk for cancer patients.
• Targeted drug delivery presents a promising strategy to mitigate the adverse effects of chemotherapy.

Purpose of the Study:

• To review clinical studies of various nanoparticle-based drug delivery systems used to concentrate anticancer drugs in neoplastic tissues.
• To evaluate the efficacy of these systems in reducing drug toxicity and expanding patient eligibility for chemotherapy.

Main Methods:

• Review of clinical studies involving liposomes, micelles, albumin-based, polymeric, dendritic, and lipid core nanoparticles as anticancer drug carriers.
• Analysis of studies demonstrating the targeting properties and toxicity reduction capabilities of these nanocarriers.

Main Results:

• Most reviewed drug delivery systems demonstrated a reduction in drug toxicity.
• Lipid core nanoparticles (LDE) exhibited potent targeting capabilities by binding to cell lipoprotein receptors and concentrating in neoplastic tissues.
• LDE showed a particularly strong reduction in toxicity when used with carmustine, etoposide, and paclitaxel.

Conclusions:

• Drug delivery systems effectively reduce chemotherapy-induced toxicity, broadening the potential patient population for treatment.
• This includes vulnerable groups like the elderly or those previously treated, who may now be candidates for curative or extended chemotherapy regimens.
• Nanoparticle-based delivery systems can enable prolonged treatment durations or increased drug dosages, improving therapeutic outcomes.